Austin S M, Lieberman J S, Newton L D, Mejia M, Peters W A, Myers B D
Department of Medicine, Stanford University School of Medicine, CA 94305.
J Am Soc Nephrol. 1993 Jan;3(7):1358-70. doi: 10.1681/ASN.V371358.
Glomerular function was evaluated longitudinally over a 24- to 48-month period in 18 patients with diabetic glomerular disease (DGD) manifested by proteinuria. GFR was determined by iothalamate clearance at 4-month intervals. The patients were divided into two groups: Group 1 (N = 9) had subnephrotic proteinuria and an initially normal GFR of 91 +/- 8 mL/min. Group 2 (N = 9) had nephrotic-range proteinuria, and initial GFR was reduced to 53 +/- 5 mL/min. Serial GFR fluctuated over time in Group 1, but no trend towards hypofiltration was evident. In contrast, GFR declined linearly in Group 2 at 1.1 +/- 0.3 mL/min per month. The transglomerular sieving of uncharged dextrans of graded size was analyzed and initially revealed a uniform reduction in glomerular pore density and an enhancement of shuntlike pores. Pore density was initially reduced by 80% and declined further after 24 months in nephrotic Group 2; corresponding pore density in subnephrotic Group 1 was reduced by half but remained constant. Renal biopsy of four members of Group 1 revealed a 22% prevalence of global glomerulosclerosis. Remaining open glomeruli exhibited hypertrophy, excessive extracellular matrix, and deformation of epithelial podocytes. The latter abnormality appeared to be the predominant determinant of lowered ultrafiltration capacity. It was inferred that trials of therapy to attenuate the progression of DGD should be initiated at a functional level similar to that in subnephrotic Group 1. Because GFR is unlikely to decline over a 2- to 4-yr period, it is suggested that such trials be extended for longer periods. Alternatively, morphometric analysis of serial renal biopsies may shorten the time needed to demonstrate effective renoprotection in DGD.
对18例表现为蛋白尿的糖尿病肾小球疾病(DGD)患者在24至48个月期间进行了肾小球功能的纵向评估。每隔4个月通过碘他拉酸盐清除率测定肾小球滤过率(GFR)。患者分为两组:第1组(N = 9)有亚肾病性蛋白尿,初始GFR正常,为91±8 mL/分钟。第2组(N = 9)有肾病范围蛋白尿,初始GFR降至53±5 mL/分钟。第1组的系列GFR随时间波动,但未显示出低滤过趋势。相比之下,第2组的GFR以每月1.1±0.3 mL/分钟的速度呈线性下降。分析了不同大小的不带电荷右旋糖酐的跨肾小球筛分情况,最初显示肾小球孔密度均匀降低,且分流样孔增多。第2组肾病患者的孔密度最初降低了80%,24个月后进一步下降;第1组亚肾病患者相应的孔密度降低了一半,但保持稳定。对第1组4名成员的肾活检显示,全球肾小球硬化的患病率为22%。其余开放的肾小球表现为肥大、细胞外基质过多以及上皮足细胞变形。后一种异常似乎是超滤能力降低的主要决定因素。据推断,应在与第1组亚肾病患者相似的功能水平上启动减轻DGD进展的治疗试验。由于GFR在2至4年期间不太可能下降,因此建议将此类试验延长更长时间。或者,对系列肾活检进行形态计量分析可能会缩短证明DGD中有效肾脏保护所需的时间。